
Washington, DC-The American Academy of Ophthalmology (AAO) sent a letter to the Centers for Medicare and Medicaid Services (CMS) supporting reimbursement for intravitreal injections of bevacizumab (Avastin, Genentech) in patients with age-related macular degeneration (AMD) whose disease has not responded to other therapies.




